Nuvectis Pharma, Inc. is a high-risk biopharmaceutical company based in the United States, specializing in the development of innovative precision medicines for oncology. Operating with a focus on ESG principles, the company is dedicated to creating novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Key pipeline products include NXP800 and NXP900.